Pharma Business - November 21, 2014
Camurus, Braeburn Enter Deal
Camurus and Braeburn Pharmaceuticals announced that they have entered into an exclusive license agreement for the long-Camurus buprenorfinprodukt, CAM2038, for the treatment of opiate dependence and pain. Braeburn receive exclusive licensing rights in North America and an option for Japan, Korea, Taiwan and China. Camurus retains all rights in the rest of the world. Under […]
Collaboration - September 17, 2013
Camurus receives option-exercise milestone for CAM2029
Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal Injection depot technology. The option exercise triggers an undisclosed milestone payment to Camurus from […]
Drug Development Pharma - September 10, 2013
Novartis acquires drug candidate from Camurus
Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal Injection depot technology. The option exercise is the next stage in the collaboration, option […]
